Luisa M. Stamm, MD, PhD

Merck & Co., Inc.

Disclosure(s): Merck & Co., Inc.: Employment, Stocks/Bonds (Public Company)

Poster(s):

• (P-364) Efficacy and Safety by Sex Assigned at Birth After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results from Two Phase 3 Randomized, Active-Controlled Studies in Adults Living with HIV-1
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-369) Safety and Efficacy of Doravirine/Islatravir (DOR/ISL) 100/0.25 mg Once Daily (QD) after ISL Dose Reduction from 0.75 mg: Week 48 Results from an Open-Label Phase 3 Study
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET

• (P-377) Efficacy and Safety by Age After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results from Two Phase 3 Randomized, Active-Controlled Studies in Adults Living with HIV-1
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET